CRESTOR

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 本研究的主要目的是研究与安慰剂相比，瑞舒伐他汀20 mg长期治疗是否会降低低血糖个体的主要心血管事件（心血管死亡、卒中、心肌梗死、不稳定型心绞痛或动脉血运重建的联合终点）的发生率（基于随机化后至首次事件的时间）。 LDL-C（130 mg/dL[3.36 mmol/L]），根据CRP水平升高（大于或等于2.0 mg/L）确定的炎症反应增强，具有高血管风险。 本研究的次要目的是通过比较总死亡率、非心血管死亡率和不良事件，研究瑞舒伐他汀与安慰剂相比长期治疗的安全性，并研究瑞舒伐他汀治疗是否降低糖尿病、静脉血栓栓塞事件和骨折的发生率。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The primary objective of the study is to investigate whether long-term treatment with rosuvastatin 20mg compared with placebo will decrease the rate(based on time to first event after randomization) of major cardiovascular events(combined endpoint of cardiovascular death, stroke, myocardial infarction, unstable angina, or arterial revascularization) among individuals with low LDL-C(130 mg/dL[3.36 mmol/L]) who are at high vascular risk on the basis of an enhanced inflammatory response, as determined by elevated levels of CRP(greater than or equal to 2.0 mg/L). The secondary objectives of the study are to investigate the safety of long-term treatment with rosuvastatin compared with placebo through comparisons of total mortality, noncardiovascular mortality, and adverse events, and to investigate whether therapy with rosuvastatin reduces the incidence of diabetes mellitus, venous thromboembolic events and the incidence of bone fractures.